DBVT Key Statistics, Chart & Performance
The current stock price of DBVT is 19.17 USD. In the past month the price increased by 48.55%. In the past year, price increased by 501.88%.
DBVT Latest News, Press Relases and Analysis
DBVT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About DBVT
Company Profile
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Company Info
DBV TECHNOLOGIES SA-SPON ADR
Batiment IRO, 107 Av. de la Republique
Chatillon AUVERGNE-RHONE-ALPES 92120 FR
CEO: Daniel Tasse
Employees: 109
Phone: 33155427878
DBV TECHNOLOGIES SA-SPON ADR / DBVT FAQ
Can you describe the business of DBV TECHNOLOGIES SA-SPON ADR?
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Can you provide the latest stock price for DBV TECHNOLOGIES SA-SPON ADR?
The current stock price of DBVT is 19.17 USD. The price increased by 0.74% in the last trading session.
What is the dividend status of DBV TECHNOLOGIES SA-SPON ADR?
DBVT does not pay a dividend.
What is the ChartMill technical and fundamental rating of DBVT stock?
DBVT has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about DBV TECHNOLOGIES SA-SPON ADR (DBVT) stock?
8 analysts have analysed DBVT and the average price target is 24.92 USD. This implies a price increase of 30% is expected in the next year compared to the current price of 19.17.
What is the expected growth for DBVT stock?
The Revenue of DBV TECHNOLOGIES SA-SPON ADR (DBVT) is expected to decline by -55.09% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of DBV TECHNOLOGIES SA-SPON ADR (DBVT)?
You can find the ownership structure of DBV TECHNOLOGIES SA-SPON ADR (DBVT) on the Ownership tab.
DBVT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to DBVT. When comparing the yearly performance of all stocks, DBVT is one of the better performing stocks in the market, outperforming 99.54% of all stocks.
DBVT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DBVT. DBVT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
DBVT Financial Highlights
Over the last trailing twelve months DBVT reported a non-GAAP Earnings per Share(EPS) of -2.51. The EPS increased by 43.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -86.01% | ||
| ROE | -143.02% | ||
| Debt/Equity | 0.08 |
DBVT Forecast & Estimates
8 analysts have analysed DBVT and the average price target is 24.92 USD. This implies a price increase of 30% is expected in the next year compared to the current price of 19.17.
For the next year, analysts expect an EPS growth of -36.93% and a revenue growth -55.09% for DBVT